Skip to content

Frontiers in Pharmacology

ISSN 1663-9812

169 papers in the library · 6,125 citations · publishing 2012-2026

Papers

Sort Most recent Most cited

Drug-induced musical hallucination.

Frontiers in Pharmacology 2024 Brock Bakewell, Michael P. Johnson, Madison Lee et al. 4 citations

Musical hallucination is a rare perceptual phenomenon wherein individuals hear music in the absence of external auditory stimuli. This phenomenon occurs across diverse medical conditions and can be triggered by some drugs. The underlying mechanism of drug-induced hallucination is unknown. This study explores drug-induced musical hallucination through a literature review, aiming to investigate...

DOI: 10.3389/fphar.2024.1401237 (opens in new tab) Full text (opens in new tab) Drug side effect Drugs-induced musical hallucination Mechanism Treatment +5

Cannabidiol or ketamine for preventing the impact of adolescent early drug initiation on voluntary ethanol consumption in adulthood.

Frontiers in Pharmacology 2024 Carles Colom-Rocha, Cristian Bis-Humbert, M Julia García-Fuster 3 citations

Few studies have previously evaluated the long-term impact of initiating the combined use of alcohol and cocaine early-in-life during adolescence. Our preclinical study characterized changes in affective-like behavior and/or voluntary ethanol consumption emerging later on in adulthood induced by a prior adolescent drug exposure, as well as tested therapeutical interventions (i.e., cannabidiol...

SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile.

Frontiers in Pharmacology 2024 Ying Xiao, Xuefeng Hu, Wei Xing et al. 1 citation

Esketamine, the first Food and Drug Administration-approved fast-acting antidepressant, has limited use because of its addictive properties. Although the combination of dextromethorphan and bupropion partially addresses the limitations of esketamine, concerns remain regarding neurologic side effects related to dextromethorphan metabolites, and seizure risks associated with high-dose bupropion....

Decreasing brain activity caused by acute administration of ketamine and alcohol - A randomized, controlled, observer-blinded experimental study.

Frontiers in Pharmacology 2024 Luan Oliveira Ferreira, Esther Padilha da Silveira, Clarissa A Paz et al.

Substance abuse is a major public health problem. In recent years, ketamine, which is a parenteral anesthetic, has been consumed increasingly as an illicit drug together with alcohol, although little is known of how this association alters brain activity. The present study investigated the influence of progressive doses of ketamine, associated with alcohol, on electrophysiological activity. For...

Chronic exposure to inhaled vaporized cannabis high in Δ9-THC suppresses Adderall-induced brain activity.

Frontiers in Pharmacology 2024 Jack M Ognibene, Rajeev I Desai, Praveen P Kulkarni et al.

There are increasing reports of the misuse of prescription psychostimulants for cognitive enhancement together with recreational cannabis. This raises a concern that chronic use of cannabis high in Δ9-THC may alter the sensitivity to amphetamines. In this exploratory study we hypothesized chronic exposure to Δ9-THC through vaporized cannabis would diminish the central nervous system (CNS)...

DOI: 10.3389/fphar.2024.1413812 (opens in new tab) Full text (opens in new tab) Bold Accumbens Awake animal imaging Basal ganglia +1

Bedside to bench: the outlook for psychedelic research

Frontiers in Pharmacology October 2, 2023 Victor P Acero, Emily S Cribas, Kevin D Browne et al. 20 citations

There has recently been a resurgence of interest in psychedelic compounds based on studies demonstrating their potential therapeutic applications in treating post-traumatic stress disorder, substance abuse disorders, and treatment-resistant depression. Despite promising efficacy observed in some clinical trials, the full range of biological effects and mechanism(s) of action of these compounds...

Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder

Frontiers in Pharmacology August 22, 2023 Mary G. Hornick, Ashley Stefanski 9 citations

The United States is entering its fourth decade of the opioid epidemic with no clear end in sight. At the center of the epidemic is an increase in opioid use disorder (OUD), a complex condition encompassing physical addiction, psychological comorbidities, and socioeconomic and legal travails associated with the misuse and abuse of opioids. Existing behavioral and medication-assisted therapies...

CBD enhances the cognitive score of adolescent rats prenatally exposed to THC and fine-tunes relevant effectors of hippocampal plasticity.

Frontiers in Pharmacology July 31, 2023 Valentina Castelli, Gianluca Lavanco, Cesare D'Amico et al.

Introduction: An altered neurodevelopmental trajectory associated with prenatal exposure to ∆-9-tetrahydrocannabinol (THC) leads to aberrant cognitive processing through a perturbation in the effectors of hippocampal plasticity in the juvenile offspring. As adolescence presents a unique window of opportunity for "brain reprogramming", we aimed at assessing the role of the non-psychoactive...

Editorial: Pharmacology of new psychoactive substances

Frontiers in Pharmacology May 9, 2023 Kabirullah Lutfy, Robert N. Pechnick, Nissar A. Darmani 1 citation

Pharmacology of new psychoactive substancesSeveral classes of novel psychoactive substances have been introduced in illicit markets throughout the world and more are being developed.They present major law enforcement challenges and global public health threats.However, there is limited information on their harmful effects on the central nervous, cardiovascular, respiratory, and gastrointestinal...

Unveiling behavioral and molecular neuroadaptations related to the antidepressant action of cannabidiol in the unpredictable chronic mild stress model

Frontiers in Pharmacology April 18, 2023 María Salud García-Gutiérrez, Daniela Navarro, Amaya Austrich-Olivares et al.

Introduction: This study aims to further characterize cannabidiol’s pharmacological and molecular profile as an antidepressant.Methods: Effects of cannabidiol (CBD), alone or combined with sertraline (STR), were evaluated in male CD1 mice (n = 48) exposed to an unpredictable chronic mild stress (UCMS) procedure. Once the model was established (4 weeks), mice received CBD (20 mg·kg-1, i.p.), STR...

Deletion of Cryab increases the vulnerability of mice to the addiction-like effects of the cannabinoid JWH-018 via upregulation of striatal NF-κB expression

Frontiers in Pharmacology March 16, 2023 Leandro Val Sayson, Darlene Mae Ortiz, Hyun Jun Lee et al. 4 citations

Synthetic cannabinoids have exhibited unpredictable abuse liabilities, especially self-administration (SA) responses in normal rodent models, despite seemingly inducing addiction-like effects in humans. Thus, an efficient pre-clinical model must be developed to determine cannabinoid abuse potential in animals and describe the mechanism that may mediate cannabinoid sensitivity. The Cryab...

DOI: 10.3389/fphar.2023.1135929 (opens in new tab) Addiction Synaptic plasticity Conditioned place preference Neuroinflammation +11

Pharmacological effects of methylone and MDMA in humans

Frontiers in Pharmacology February 17, 2023 Lourdes Poyatos, Clara Pérez‐mañá, Olga Hladun et al. 26 citations

Methylone is one of the most common synthetic cathinones popularized as a substitute for 3,4-methylenedioxymethamphetamine (MDMA, midomafetamine) owing to its similar effects among users. Both psychostimulants exhibit similar chemistry (i.e., methylone is a β-keto analog of MDMA) and mechanisms of action. Currently, the pharmacology of methylone remains scarcely explored in humans. Herein, we...

Rearing behaviour in the mouse behavioural pattern monitor distinguishes the effects of psychedelics from those of lisuride and TBG

Frontiers in Pharmacology February 16, 2023 Yahong Chen, Junhong Liu, Yishan Yao et al. 19 citations

Psychedelics alter consciousness and may have potential for drug development. As psychedelics are likely therapeutically active, it is important to study their effects and mechanisms using preclinical models. Here, we examined the effects of phenylalkylamine and indoleamine psychedelics on locomotor activity and exploratory behaviour using the mouse Behavioural Pattern Monitor (BPM). DOM,...

Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice

Frontiers in Pharmacology January 4, 2023 Kenneth Alper, Janelle Cange, Ria Sah et al. 39 citations

The classical psychedelic psilocybin is of interest as a treatment for alcohol use disorder (AUD). This study investigated the effects of psilocybin on voluntary ethanol consumption in adult male and female C57BL/6J mice administered saline or psilocybin intraperitoneally as a single dose of 0.1, 0.5, 1.0 or 2.0 mg/kg and provided 20% ethanol utilizing a two-bottle choice alcohol drinking...

Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine.

Frontiers in Pharmacology 2023 Dario Dornbierer, Laurenz Marten, Jovin Mueller et al. 32 citations

Recently, the Amazonian plant medicine "ayahuasca"-containing the psychedelic compound N,N-dimethyltryptamine (DMT) and numerous β-carboline alkaloids, such as harmine-has been suggested to exhibit beneficial effects in patients with affective and other mental health disorders. Although ayahuasca ingestion is considered safe, its pharmacokinetics/pharmacodynamics and tolerability profile pose...

DOI: 10.3389/fphar.2023.1246892 (opens in new tab) Full text (opens in new tab) Psychedelics/entheogens/hallucinogens Drug-delivery/formulations/administration Ayahuasca/DMT/Harmine Pharmaceutical-innovation/drug-development

A pilot study of cerebral metabolism and serotonin 5-HT2A receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine.

Frontiers in Pharmacology 2023 Klemens Egger, Frederik Gudmundsen, Naja Støckel Jessen et al. 17 citations

Rationale: The psychedelic effects of the traditional Amazonian botanical decoction known as ayahuasca are often attributed to agonism at brain serotonin 5-HT2A receptors by N,N-dimethyltryptamine (DMT). To reduce first pass metabolism of oral DMT, ayahuasca preparations additionally contain reversible monoamine oxidase A (MAO-A) inhibitors, namely β-carboline alkaloids such as harmine....

μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.

Frontiers in Pharmacology 2023 Leah M Salinsky, Christina R Merritt, Joshua C Zamora et al. 14 citations

Opioid misuse and opioid-involved overdose deaths are a massive public health problem involving the intertwined misuse of prescription opioids for pain management with the emergence of extremely potent fentanyl derivatives, sold as standalone products or adulterants in counterfeit prescription opioids or heroin. The incidence of repeated opioid overdose events indicates a problematic use...

Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation.

Frontiers in Pharmacology 2023 Kateřina Syrová, Klára Šíchová, Hynek Danda et al. 4 citations

Introduction: N-2-methoxy-benzylated ("NBOMe") analogues of phenethylamine are a group of new psychoactive substances (NPS) with reported strong psychedelic effects in sub-milligram doses linked to a number of severe intoxications, including fatal ones. In our present work, we provide a detailed investigation of pharmacokinetics and acute behavioural effects of 2C-B-Fly-NBOMe...

DOI: 10.3389/fphar.2023.1120419 (opens in new tab) Full text (opens in new tab) 2c-b-fly-nbome Nbome series New psychoactive substance Pharmacokinetics +10

Binding and functional structure-activity similarities of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues at 5-HT2A and 5-HT2B serotonin receptors.

Frontiers in Pharmacology 2023 Prithvi Hemanth, Pallavi Nistala, Vy T Nguyen et al. 4 citations

Certain 4-substituted analogs of 1-(2,5-dimethoxyphenyl)isopropylamine (2,5-DMA) are psychoactive classical hallucinogens or serotonergic psychedelic agents that function as human 5-HT2A (h5-HT2A) serotonin receptor agonists. Activation of a related receptor population, h5-HT2B receptors, has been demonstrated to result in adverse effects including cardiac valvulopathy. We previously published...

Corrigendum: Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders.

Frontiers in Pharmacology 2023 Nataliya S. Vorobyeva, Alena A. Kozlova 1 citation correction

• please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others. • edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary •...

Cannabidiol and brain function: current knowledge and future perspectives.

Frontiers in Pharmacology 2023 Moniek Schouten, Sebastiaan Dalle, Dante Mantini et al.

Cannabidiol (CBD) is a naturally occurring non-psychoactive cannabinoid found in Cannabis sativa, commonly known as cannabis or hemp. Although currently available CBD products do not meet the safety standards of most food safety authorities to be approved as a dietary supplement or food additive, CBD has been gaining widespread attention in recent years due to its various potential health...

Altered states, alkaloids, and catatonia: Monoaminoxidase inhibitors and their role in the history of psychopharmacology.

Frontiers in Pharmacology December 6, 2022

Monoamine oxidases are mitochondrial enzymes that catalyze the oxidative deamination of biogenic amines (adrenaline, noradrenaline, serotonin, and dopamine), causing their inactivation and subsequently playing a fundamental role in the homeostasis of various neurotransmitters. As the regulation of these effects was deemed important in clinical practice, numerous modulators of these enzymes were...

The treatment of depression — searching for new ideas

Frontiers in Pharmacology October 7, 2022 Katarzyna Stachowicz, Magdalena Sowa-Kućma 48 citations

Depression is a severe mental health problem that affects people regardless of social status or education, is associated with changes in mood and behavior, and can result in a suicide attempt. Therapy of depressive disorders is based mainly on drugs discovered in the 1960s and early 1970s. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)...

DOI: 10.3389/fphar.2022.988648 (opens in new tab) Serotonin Monoaminergic Antidepressant Pharmacology +1

Editorial: Psychoactive natural products: Potential in the treatment of brain diseases and strategies to improve delivery

Frontiers in Pharmacology October 3, 2022 Célia Cabral, Claudia Carbone, Pamela Maher et al.

Psychoactive natural products: Potential in the treatment of brain diseases and strategies to improve delivery For this special issue, focusing on psychoactive natural products with therapeutic potential for the treatment of brain diseases, we have invited authors to contribute with research and review articles illustrating and stimulating the continuing effort in drug discovery and drug...